Announcements Trials
Browse Landscape

Phase

Phase 4 3Phase 2 1

Status

Completed 5Withdrawn 1

Sponsor Class

INDUSTRY 4NIH 1

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Lymphoid 5Dermatologic 5

Conditions

Lymphoma, T-Cell, Cutaneous 5Lymphoma 5Lymphoma, T-Cell, Peripheral 4Leukemia, Lymphocytic, Chronic, B-Cell 4Sezary Syndrome 3Mycosis Fungoides 3Melanoma 3Lymphoma, Follicular 3Carcinoma, Ovarian Epithelial 3Breast Neoplasms 3Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Leukemia 2Kidney Neoplasms 2Fallopian Tube Neoplasms 2Drug-Related Side Effects and Adverse Reactions 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Waldenstrom Macroglobulinemia 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Mastocytosis, Systemic 1Lymphoproliferative Disorders 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1

Interventions

Peripheral Blood Stem Cell Transplantation 32fludarabine phosphate 29Cyclophosphamide 26Whole-Body Irradiation 21Cyclosporine 20Busulfan 20Mycophenolic Acid 19Tacrolimus 16Antilymphocyte Serum 14Methotrexate 13romidepsin 12Etoposide 12Filgrastim 11Melphalan 9Psychiatric Rehabilitation 8Methylprednisolone 8Dexamethasone 8Bexarotene 8Vorinostat 7Flow Cytometry 7Therapeutics 6Radiotherapy 6Calcium Dobesilate 6Brentuximab Vedotin 6Bortezomib 6Alemtuzumab 6sargramostim 5fludarabine 5denileukin diftitox 5Polymerase Chain Reaction 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Lymphoma, T-Cell, Cutaneous × denileukin diftitox × Clear all
NCT05137847 2023-12-12

A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)

Eisai Inc.

Completed
118 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Drug-Related Side Effects and Adverse Reactions

NCT00006345 2013-05-30

Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma

National Cancer Institute (NCI)

Phase 2 Completed
DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Drug-Related Side Effects and Adverse Reactions

NCT00050999 2008-03-05

Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients

Eisai Inc.

Phase 4 Completed
195 enrolled
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00051012 2008-03-05

Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients

Eisai Inc.

Phase 4 Completed
86 enrolled
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00211198 2008-03-05

Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)

Eisai Inc.

Phase 4 Completed
60 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡